Encinitas, CA, United States of America

Thomas J Lobl


Average Co-Inventor Count = 3.6

ph-index = 3

Forward Citations = 117(Granted Patents)


Company Filing History:


Years Active: 1993-1998

Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Thomas J Lobl in Cell Adhesion Research

Introduction: Thomas J Lobl is a prominent inventor based in Encinitas, California. With an impressive portfolio of four patents, his work primarily focuses on cyclic peptide compounds that play a significant role in modulating cell adhesion. His research has contributed to advancements in therapeutic applications, particularly in addressing adhesion-related pathologies.

Latest Patents: Among Thomas J Lobl's latest inventions are two noteworthy patents:

1. **Cyclic Peptide Inhibitors of β1 and β2:** This invention describes cyclic peptide compounds which modulate integrin-mediated adhesion. These compounds have the capability to inhibit both β1 and β2 mediated adhesion, providing a basis for therapeutic uses in treating various adhesion-related diseases.

2. **Cyclic Cell Adhesion Modulation Compounds:** This patent discloses cyclized integrin receptor antagonist compounds that are useful in modulating cell adhesion. The compounds address adhesion related to fibronectin and leukocyte adhesion to endothelial cells. The patent also details methods for synthesizing, testing, formulating, and using these compounds as therapeutic agents.

Career Highlights: Thomas J Lobl is currently associated with Tanabe Seiyaku Company, Limited, where he continues to advance his research in cell adhesion and related therapies. His innovative mindset and dedication to scientific inquiry have positioned him as a significant figure in his field.

Collaborations: Throughout his career, Thomas has collaborated with esteemed colleagues, including Shiu-Lan Chiang and Pina M Cardarelli. Their joint efforts have further enriched the research landscape in cell adhesion modulation and its therapeutic applications.

Conclusion: Thomas J Lobl’s contributions to the fields of cyclic peptides and cell adhesion have paved the way for future innovations in therapeutic interventions. His work exemplifies the impact of dedicated research and collaboration in the advancement of medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…